Global enrollment goal reached in Phase II Severe Asthma Study

Nov 2015. The global enrollment goal of 544 subjects in this study has been reached. The aim of the study is to evaluate the efficacy and safety of mepolizumab adjunctive therapy on markers of asthma control in subjects with severe eosinophilic asthma.

The international study is a randomized, double-blind, placebo-controlled, parallel-group, multi-center.

Recruitment for the study has now officially closed.

AmeRuss has been involved with this study as a local CRO in Russia to help  expedite the enrollment. Participating sites are located in Saint Petersburg, Stavropol, Voronezh, Novosibirsk, Irkutsk and Ekaterinburg where AmeRuss has its own monitoring capabilities.

Close-out visits are planned for February-March 2016.

Related News